Patents by Inventor Antonin Sturc

Antonin Sturc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11186583
    Abstract: 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidine derivatives of formula I that are effective inhibitors of kinases and exhibit strong antiproliferative and proapoptotic properties on lymphoma cells. Derivatives in the treatment of blood hyperproliferative diseases, such as Non-Hodgkin lymphomas are also disclosed.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: November 30, 2021
    Assignees: UNIVERZITA PALACKEHO V OLOMOUCI, USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I.
    Inventors: Libor Havlicek, Antonin Sturc, Eva Reznickova, Radek Jorda, Vladimir Krystof, Miroslav Strnad
  • Patent number: 11104650
    Abstract: An improved process for preparing 2-chloro-4-nitroimidazole derivatives which are useful intermediates in the preparation of an anti-tuberculosis drug is provided. The process may comprise the step of chlorinating nitroimidazoles with a chlorinating agent and an activating agent to give 2-chloro-4-nitroimidazole derivatives.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: August 31, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Petr Novak, Petr Zahradnik, Jiri Tauchman, Jan Koci, Antonin Sturc
  • Patent number: 11098067
    Abstract: The present invention relates to a method of production of 4-boronophenylalanine (BPA) from 4-iodophenylalanine, in which all the functional groups of the amino acid are protected by benzyl protection method, and which uses isopropyl magnesium halogenide stabilized by a complexation base, and subsequent condensation of the resulting Grignard reagent with a boric acid ester. The final reaction step, catalytic hydrogenolysis or transfer hydrogenolysis of protecting groups on the amino acid, occurs after hydrolysis of the boronate ester groups.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 24, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Petr Zahradnik, Antonin Sturc, Jiri Malinak, Jan Koci
  • Publication number: 20210053925
    Abstract: An improved process for preparing 2-chloro-4-nitroimidazole derivatives which are useful intermediates in the preparation of an anti-tuberculosis drug is provided. The process may comprise the step of chlorinating nitroimidazoles with a chlorinating agent and an activating agent to give 2-chloro-4-nitroimidazole derivatives.
    Type: Application
    Filed: January 29, 2018
    Publication date: February 25, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Petr NOVAK, Petr ZAHRADNIK, Jiri TAUCHMAN, Jan KOCI, Antonin STURC
  • Publication number: 20200392163
    Abstract: The present invention relates to a method of production of 4-boronophenylalanine (BPA) from 4-iodophenylalanine, in which all the functional groups of the amino acid are protected by benzyl protection method, and which uses isopropyl magnesium halogenide stabilized by a complexation base, and subsequent condensation of the resulting Grignard reagent with a boric acid ester. The final reaction step, catalytic hydrogenolysis or transfer hydrogenolysis of protecting groups on the amino acid, occurs after hydrolysis of the boronate ester groups.
    Type: Application
    Filed: February 19, 2019
    Publication date: December 17, 2020
    Inventors: Petr ZAHRADNIK, Antonin STURC, Jiri MALINAK, Jan KOCI
  • Publication number: 20200361943
    Abstract: 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidine derivatives of formula I that are effective inhibitors of kinases and exhibit strong antiproliferative and proapoptotic properties on lymphoma cells. Derivatives in the treatment of blood hyperproliferative diseases, such as Non-Hodgkin lymphomas are also disclosed.
    Type: Application
    Filed: February 1, 2019
    Publication date: November 19, 2020
    Applicants: UNIVERZITA PALACKEHO V OLOMOUCI, USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I.
    Inventors: Libor HAVLICEK, Antonin STURC, Eva REZNICKOVA, Radek JORDA, Vladimir KRYSTOF, Miroslav STRNAD
  • Patent number: 9957273
    Abstract: 5-substituted-7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidines are potent inhibitors of protein kinases, especially cyclin-dependent kinases such as CDK2 and CDK5, and display antileukemic, pro-apoptotic, antiangiogenic and anticancer activities. The invention also relates to processes for their preparation, to pharmaceutical compositions and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation, apoptosis, angiogenesis and inflammation, such as leukemia and metastatic solid cancer.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: May 1, 2018
    Assignee: USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I.
    Inventors: Libor Havlicek, Antonin Sturc, Vladimir Krystof, Radek Jorda, Tomas Pospisil, Stefan Zahler, Angelika Vollmar, Miroslav Strnad
  • Publication number: 20180072736
    Abstract: 5-substituted-7-[4-(2-pyridyl)phenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidines are potent inhibitors of protein kinases, especially cyclin-dependent kinases such as CDK2 and CDK5, and display antileukemic, pro-apoptotic, antiangiogenic and anticancer activities. The invention also relates to processes for their preparation, to pharmaceutical compositions and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation, apoptosis, angiogenesis and inflammation, such as leukemia and metastatic solid cancer.
    Type: Application
    Filed: October 2, 2015
    Publication date: March 15, 2018
    Applicant: USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I.
    Inventors: Libor HAVLICEK, Antonin STURC, Vladimir KRYSTOF, Radek JORDA, Tomas POSPISIL, Stefan ZAHLER, Angelika VOLLMAR, Miroslav STRNAD
  • Patent number: 5182285
    Abstract: A cell-protective composition for preventing or treating of a peptic ulcer due to topical endogenous lesion of gastric or duodenal mucous membrane comprises as a physiologically active component the cyclo-(1-alanyl-amino-1-cyclopentanecarbonyl)cyclodipeptide. The subject composition is designated for administration by oral or parenteral route. It is substantially non-toxic and well tolerated, and acts beneficially, even at low dosage level.
    Type: Grant
    Filed: April 6, 1990
    Date of Patent: January 26, 1993
    Assignee: Spojene Podniky Pro Zdravotnickou Vyrobu
    Inventors: Evzen Kasafirek, Vaclav Plaisner, Libuse Korbova, Jirj Kohout, Jirina Cizkova, Ivan Krejci, Arnost Pospisil, Milan Pesak, Antonin Sturc, Jiri Krepelka, Antonin Dlabac, Jiri Vanzura
  • Patent number: 4898930
    Abstract: Peptide ester and amide derivatives of the general formula I: ##STR1## in which X is H or an acyl, A and B are structurally defined amino acid residues, n is an integer of from 1 to 3, R.sup.1 is H or a lower alkyl and either R.sup.2 or C is a defined optionally modified amino acid residue and the other is a lower alkoxyl, an amino group or a direct chemical bond, are converted under physiologic conditions, by enzymic hydrolysis in pathologically altered tissues and subsequent spontaneous cyclization, into pharmacodynamically active spirocyclic peptide derivatives of the general formula III: ##STR2## in which R.sup.3 and R.sup.4 are H atoms, optionally substituted alkyl groups or jointly an aliphatic chain forming preferably a 2,5- piperazinedione ring, and hence can act as pro-farmaca (drug precursors) of prolonged biological effect.
    Type: Grant
    Filed: June 12, 1987
    Date of Patent: February 6, 1990
    Assignee: Spofa, spojene podniky pro
    Inventors: Evzen Kasafirek, Miroslav Rybak, Ivan Krejci, Antonin Sturc, Alena Roubalova, Jiri Vanzura, Evzen Krepela, Michal Bartik